Introduction
============

Liver cancer was estimated to be the sixth most common cancer type and the fourth leading cause of cancer-associated death worldwide in 2018, and it has been reported that hepatocellular carcinoma (HCC) is the most common subtype, accounting for 75--85% of all primary cases of liver cancer ([@b1-etm-0-0-8046]). However, the underlying molecular mechanisms of HCC development remain to be fully elucidated, and the high incidence of metastasis and recurrence frequently results in poor prognosis for patients with HCC, even following curative therapy ([@b2-etm-0-0-8046]). Therefore, it is imperative to identify novel diagnostic and prognostic biomarkers and efficacious therapeutic targets.

Abnormalities in gene transcription and translation serve important roles in the development and progression of HCC. Developments in biotechnology, including genome sequencing and bioinformatics, have facilitated the study of the tumor transcriptome and proteome, which has advanced the current understanding of the underlying molecular mechanisms of HCC. Genome sequencing has indicated that the human genome is comprised of \<2% protein-coding genes and \>90% of the genome is transcribed as non-coding RNA (ncRNA) ([@b3-etm-0-0-8046]). Numerous classes of ncRNA have been identified and demonstrated to be associated with cancer, including long-ncRNAs (lncRNAs), microRNAs (miRNAs), small nucleolar RNAs and PIWI-interacting RNAs ([@b4-etm-0-0-8046]--[@b7-etm-0-0-8046]), among which lncRNAs and miRNAs have been most extensively studied. lncRNAs are \>200 nucleotides long and participate in multiple biological functions, including epigenetics, nuclear import, alternative splicing, RNA decay and translation ([@b5-etm-0-0-8046]). miRNAs are small ncRNAs of 18--25 nucleotides in length that regulate the expression of multiple mRNAs by reducing the stability and inhibiting the translation of mRNAs at the post-transcriptional level ([@b8-etm-0-0-8046]). miRNAs restrain the expression of target genes, whereas lncRNAs may competitively combine with miRNAs to promote the expression of target genes; in this interaction, they are commonly referred to as competing endogenous RNAs (ceRNAs) ([@b9-etm-0-0-8046]). Although previous studies have reported on the roles of lncRNAs and miRNAs in HCC ([@b10-etm-0-0-8046]--[@b14-etm-0-0-8046]), the specific underlying mechanisms associated with the initiation and progression of HCC remain to be fully elucidated ([@b15-etm-0-0-8046]).

In the present study, profiles of differentially expressed lncRNAs between HCC tissues and adjacent normal tissues were determined from high-throughput RNA sequencing data.

Bioinformatics and survival analysis using integrated mining of data from The Cancer Genome Atlas (TCGA) was performed ([@b16-etm-0-0-8046]). Simultaneously, the regulatory mechanisms and signaling pathways in HCC were predicted and their differential diagnostic performance was analyzed to provide a potentially valuable reference for the early diagnosis, effective treatment and prognosis of patients with HCC.

Materials and methods
=====================

### RNA-sequencing (seq) data retrieval and processing

The GSE94660 dataset was obtained from the Gene Expression Omnibus (GEO), which contains the RNA sequencing data from 21 pairs of tumor and non-neoplastic liver tissues from patients with hepatitis B virus-associated HCC. The normalized gene expression dataset GSE94660 was downloaded from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) ([@b17-etm-0-0-8046]). To identify the differentially expressed genes between tumor and non-tumor tissues, threshold values of a fold change of \|1.5\| and P\<0.05 were used.

### Expression level analysis

The expression of lncRNA and mRNA in patients were analyzed using either Gene Expression Profiling Interactive Analysis (GEPIA) ([@b18-etm-0-0-8046]) or from expression data downloaded from TCGA ([@b16-etm-0-0-8046]). Expression data of lncRNA in normal tissues were obtained from BioProject (accession no. PRJEB4337; linc01093) ([@b19-etm-0-0-8046]).

### Target prediction and network establishment

To predict potential miRNAs that target candidate lncRNAs, lncBase version 2 (<http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=lncbasev2/index>) ([@b20-etm-0-0-8046]) was used with a prediction score of ≥0.95 as the threshold value. The miRNAs identified were further inputted into TargetScan (<http://www.targetscan.org/vert_72/>) ([@b21-etm-0-0-8046]) to identify their potential target genes. Targets with a cumulative weighted context score ≤-0.6 that interacted with a differentially expressed gene identified in the GSE94660 dataset were selected to establish an interaction network with candidate miRNAs and lncRNA using Cytoscape 3.40 ([@b22-etm-0-0-8046]).

### Interactome identification and functional enrichment analysis

Proteins that physically interacted with zinc finger AN1-type containing 5 (ZFAND5) were identified from BioGRID (<https://thebiogrid.org/>) ([@b23-etm-0-0-8046]), an interaction repository containing 1,623,645 protein and genetic interactions in a number of species. Gene ontology (GO) ([@b24-etm-0-0-8046]) and reactome pathway enrichment analyses of the ZFAND5 interactome were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>) ([@b25-etm-0-0-8046]), which provides a comprehensive set of functional annotation tools for researchers to understand the biological contexts surrounding a large number of interacting genes.

### Survival analysis

To assess the prognostic value of the lncRNAs and genes identified, GEPIA and Kaplan-Meier plotter (<http://kmplot.com/analysis/>) ([@b26-etm-0-0-8046]) were used. Overall survival of patients with HCC was analyzed using a Kaplan-Meier plot based on the median expression levels of each gene. The hazard ratio (HR) and 95% confidence intervals were calculated and a log-rank test was used to determine whether survival was significantly different between patients with high and low expression of each gene in their HCC tissues.

Results
=======

### Downregulated expression of LINC01093 in HCC tissues is associated with poor prognosis

The GSE94660 dataset from GEO database was analyzed, and heatmaps were generated to present the differentially expressed genes ([Fig. 1A](#f1-etm-0-0-8046){ref-type="fig"}) and lncRNAs ([Fig. 1B](#f1-etm-0-0-8046){ref-type="fig"}) with a fold change ≥\|1.5\| and P\<0.05. LINC01093 ([@b27-etm-0-0-8046],[@b28-etm-0-0-8046]) was the most significantly downregulated lncRNA ([Fig. 1C](#f1-etm-0-0-8046){ref-type="fig"}). The expression profile of LINC01093 in normal tissues was obtained from BioProject, and LINC01093 was almost exclusively expressed in normal liver tissue in humans ([Fig. 1D](#f1-etm-0-0-8046){ref-type="fig"}). To validate these results, the expression of LINC01093 in HCC tissues and adjacent non-tumor tissues was analyzed using the GEPIA database. The results indicated that LINC01093 was significantly downregulated in tumor tissues compared with that in normal tissues ([Fig. 1E](#f1-etm-0-0-8046){ref-type="fig"}). Survival analysis using Kaplan-Meier plotter suggested that low expression levels of LINC01093 in patients with HCC predicted a less favorable prognosis ([Fig. 1F](#f1-etm-0-0-8046){ref-type="fig"}).

### LINC01093 is a potential target of miR-96-5p

lncRNAs primarily function as ceRNAs; thus, low expression levels of LINC01093 in tumor tissues lead to high expression of target miRNAs. To identify potential miRNAs that interact with LINC01093, the lncBase database was used. By implementing a cutoff prediction score of ≥0.95, five potential miRNAs were identified: miR-30b-3p, miR-627-3p, miR-676-5p, miR-3689d and miR-96-5p. The potential target genes of these miRNAs were predicted using TargetScan and screened with a total context score of ≤0.6 used as the cutoff. Genes identified in TargetScan, which were also differentially expressed in the GSE94660 dataset, were selected as candidate targets. A lncRNA-miRNA-gene network was established ([Fig. 2A](#f2-etm-0-0-8046){ref-type="fig"}) with the aforementioned diverse bioinformatics tools ([Fig. 2B](#f2-etm-0-0-8046){ref-type="fig"}). The expression levels of the five aforementioned miRNAs were validated using data from TCGA, revealing that three of the miRNAs were significantly differentially expressed between tumor tissues and adjacent non-tumor tissues; among these miRs, miR-96-5p was upregulated in tumor tissues, whereas miR-30b-3p and miR-627-3p were significantly downregulated in tumor tissues ([Fig. 2C](#f2-etm-0-0-8046){ref-type="fig"}). The Kaplan-Meier plotter was used to perform survival analysis, and the results indicated that low expression levels of miR-96-5p predicted a favorable prognosis for patients with HCC ([Fig. 2D](#f2-etm-0-0-8046){ref-type="fig"}). Although the expression levels were negatively associated with patient prognosis, miR-627-3p was not statistically considered a potential candidate miRNA ([Fig. 2E](#f2-etm-0-0-8046){ref-type="fig"}). There was no significant association between the expression of miR-30b-3p and survival outcome ([Fig. 2F](#f2-etm-0-0-8046){ref-type="fig"}). These results indicate that miR-96-5p potentially targets LINC01093. The results indicated that miR-96-5p has a tumor suppressor role in HCC by inhibiting LINC01093, and its upregulation is associated with a favorable prognosis regarding survival.

### ZFAND5 is a candidate target of miR-96-5p

miRNA regulates gene expression in a negative manner; thus, high expression levels of miR-96-5p in the tumor tissue theoretically result in decreased expression of the target gene. To identify the potential targets, expression of previously predicted miR-96-5p target genes were analyzed and the results suggested that the expression levels of netrin 4 (NTN4) and ZFAND5 were lower in HCC tissues compared with those in the adjacent non-tumor tissues ([Fig. 3A](#f3-etm-0-0-8046){ref-type="fig"}). LIM domain containing preferred translocation partner in lipoma (LPP) was significantly differentially expressed; however, its expression was upregulated in tumor tissues ([Fig. 3A](#f3-etm-0-0-8046){ref-type="fig"}). These results were further validated using data from TCGA, confirming that NTN4 and ZFAND5 were downregulated in HCC tissues ([Fig. 3B](#f3-etm-0-0-8046){ref-type="fig"}). NTN4 and ZFAND5 were further subjected to survival analysis, and the results demonstrated that only high expression of ZFAND5 predicted a favorable prognosis for patients with HCC ([Fig. 3C](#f3-etm-0-0-8046){ref-type="fig"}), whereas high expression of NTN4 was not predicted to be significantly associated with improved prognosis ([Fig. 3D](#f3-etm-0-0-8046){ref-type="fig"}). Therefore, ZFAND5 was selected for further analysis.

### Functional analysis of the ZFAND5 interactome indicates the significance of NF-κB signaling

To further explore its function, the interactome of ZFAND5 was determined using BioGRID. This led to the identification of a total of 14 physical interactors with various experimental systems ([Fig. 4A](#f4-etm-0-0-8046){ref-type="fig"}). Functional analysis demonstrated that the top 10 enriched GO terms were 'Fc-epsilon receptor signaling pathway', 'stimulatory C-type lectin receptor signaling pathway', 'nucleotide-binding oligomerization domain containing signaling pathway', 'T cell receptor signaling pathway', 'MyD88-dependent Toll like receptor (TLR) signaling pathway', 'protein polyubiquitination', 'JNK cascade', 'inhibitor of NF-κB kinase (IKK)/NF-κB signaling', 'Wnt signaling pathway' and 'activation of mitogen-activated protein kinase (MAPK) activity' ([Fig. 4B](#f4-etm-0-0-8046){ref-type="fig"}); while the most significantly enriched reactome pathways were tumor necrosis factor receptor associated factor 6 (TRAF6)-mediated NF-κB activation'; MAPK kinase kinase 7 (TAK1) activates NF-κB by phosphorylation and activation of IKKs complex, interleukin-1 family signaling, C-type lectin domain containing 7A (CLEC7A) signaling, nerve growth factor receptor (p75NTR) recruits signaling complexes, NF-κB is activated and signals survival, neurotrophin receptor-interacting factor (NRIF) signals cell death from the nucleus, interleukin 1 receptor associated kinase 1 (IRAK1) recruits IKK complex upon TLR7/8 or −9 stimulation, IRAK1 recruits IKK complex, and downstream T-cell receptor (TCR) signaling ([Fig. 4C](#f4-etm-0-0-8046){ref-type="fig"}). A network consisting of the genes involved in the top 10 GO terms was visualized using Cytoscape ([Fig. 4D](#f4-etm-0-0-8046){ref-type="fig"}). Similarly, the reactome pathway network is presented in [Fig. 4E](#f4-etm-0-0-8046){ref-type="fig"}. Colored nodes represent different GO terms or pathways and the node color represents enrichment significance. Combined GO and pathway analysis indicated that NF-κB signaling had a prominent significance.

Discussion
==========

HCC is notoriously difficult to treat successfully and is one of the leading causes of cancer-associated death worldwide. To date, the mechanisms underlying the initiation and progression of HCC have remained to be fully elucidated. lncRNAs have been indicated to regulate gene expression and have been implicated in various biological processes and human diseases. RNA-seq is a high-throughput sequencing technique that may reveal the presence and quantity of specific RNAs in a sample, which allows for the analysis of gene expression, alternative gene splicing and gene fusion. RNA-seq has been widely used to identify pathogenesis-associated genes, and to determine potential therapeutic targets in various diseases.

In the present study, the mRNA and lncRNA expression profiles between HCC tissues and adjacent non-tumor tissues from the GSE94660 dataset were compared and it was demonstrated that LINC01093 was significantly downregulated in tumor tissues. Analysis with BioProject indicated that LINC01093 was almost exclusively expressed in the normal adult liver. The expression of LINC01093 was then validated using data from TCGA, which confirmed its downregulation in HCC, and further survival analysis demonstrated that high expression levels of LINC01093 in HCC tissues were associated with a favorable clinical prognosis.

To understand the role of LINC01093 in hepatocellular carcinogenesis, miRNAs that target LINC01093 were predicted and screened. miR-30b-3p, miR-627-3p, miR-676-5p, miR-3689d and miR-96-5p were identified as potential candidates. The expression levels of these five miRNAs were validated using TCGA, and the results demonstrated that miR-30b-3p, miR-627-3p and miR-96-5p were significantly differentially expressed between tumor tissues and non-tumor tissues, but only miR-96-5p was upregulated in tumor tissues. Survival analysis of the three miRNAs was also performed and the results demonstrated that low expression levels of miR-96-5p predicted a favorable prognosis of patients. miR-96-5p has previously been recognized as an oncogenic miRNA in different types of cancer. In bladder cancer, studies revealed that miR-96-5p promoted tumor cell migration and invasion ([@b29-etm-0-0-8046]). In prostate cancer, it has been reported that miR-96-5p governed tumor progression and disease outcome by targeting a retinoic acid receptor γ network ([@b30-etm-0-0-8046]). In colorectal cancer, miR-96-5p was indicated to promote tumor invasion through inhibition of reversion-inducing cysteine-rich protein expression ([@b31-etm-0-0-8046]). In the present study, the results also suggested that miR-96-5p may promote HCC progression and to be associated with poor disease outcome.

Target genes of miR-96-5p were then predicted and screened with a cumulative weighted context score of ≤-0.6, and LPP, NTN4 and ZFAND5 were the identified as target genes among the differentially expressed genes identified in the GSE94660 dataset. These genes were therefore selected as candidate genes. miRNA regulates gene expression in a negative manner, and since miR-96-5p was upregulated in tumor tissues, downregulation of target genes was expected. The expression of the three candidate genes was analyzed, revealing that ZFAND5 and NTN4 had lower expression in tumor tissues compared with that in adjacent non-tumor tissues, whereas LPP was upregulated in HCC tissues, and these results were further confirmed in the TCGA dataset. ZFAD5 and NTN4 were subjected to survival analysis, which revealed that high mRNA expression levels of ZFAND5 were a favorable predictor of patient prognosis.

ZFAND5 is a member of the ZFAND family ([@b28-etm-0-0-8046]), and studies have revealed that ZFAND5 enhances protein degradation by activating the ubiquitin-proteasome system ([@b32-etm-0-0-8046],[@b33-etm-0-0-8046]). To understand the potential role of ZFAND5 in HCC, proteins that physically interacted with ZFAND5 were obtained from BioGRID, which included 14 interactors identified by 7 different experimental systems. The ZFAND5-interactome was subsequently subjected to functional enrichment analysis. GO analysis revealed that the top 10 biological processes were 'Fc-epsilon receptor signaling pathway', 'stimulatory C-type lectin receptor signaling pathway', 'nucleotide-binding oligomerization domain containing signaling pathway', 'T cell receptor signaling pathway', 'MyD88-dependent TLR signaling pathway', 'protein polyubiquitination', 'JNK cascade', 'IKK/NF-κB signaling', 'Wnt signaling pathway' and 'activation of MAPK activity', while the most significantly enriched reactome pathways were 'TRAF6 mediated NF-κB activation', 'TAK1 activates NF-κB by phosphorylation and activation of IKKs complex', 'interleukin-1 family signaling', 'CLEC7A signaling', 'p75NTR recruits signaling complexes', 'NF-κB is activated and signals survival', 'NRIF signals cell death from the nucleus', 'IRAK1 recruits IKK complex upon TLR7/8 or −9 stimulation', 'IRAK1 recruits IKK complex' and 'downstream TCR signaling'. These results demonstrate that the NF-kB signaling is an important downstream pathway of ZFAND5.

NF-κB serves a well-known function in immune regulation and inflammatory responses, but growing evidence has additionally demonstrated its role in tumorigenesis ([@b34-etm-0-0-8046],[@b35-etm-0-0-8046]). Therefore, NF-κB is frequently considered as the critical link between inflammation and cancer ([@b35-etm-0-0-8046]--[@b37-etm-0-0-8046]). It was reported that ZFAND5 inhibits NF-κB activation by interacting with IKKγ ([@b38-etm-0-0-8046]). Therefore, the present study indicated the role of a LINC01093/miR96-5p/ZFAND5/NF-κB axis in the regulation of HCC development and progression, and further investigations are required to verify these results. Lack of experimental data is a limitation of the present study, and in a further study, *in vitro* and *in vivo* experiments will be performed to verify the conclusions that were obtained through the bioinformatics analysis. Through the use of bioinformatics analysis and *in vitro* and *in vivo* experiments, novel insight into the development of potential treatments for patients with HCC may be gained.
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![LINC01093 is downregulated in HCC tissues and positively associated with patient prognosis. Heat maps for (A) mRNAs and (B) lncRNAs deregulated in HCC vs. adjacent non-tumor tissues. (C) Expression of LINC01093 in HCC tissues and adjacent non-tumor tissues. (D) Expression of LINC01093 across normal organs and tissues. (E) Validation of LINC01093 expression in HCC tissues (n=369) and adjacent non-tumor tissues (n=50) using data from The Cancer Genome Atlas. The tumor tissues are presented on the left and the non-tumor tissues on the right. \*P\<0.05. (F) Kaplan-Meier analysis of overall survival for patients with HCC with high vs. low LINC01093 expression. Dotted lines stand for the 95% CI for the HR. HCC, hepatocellular carcinoma; lncRNA, long non-coding RNA; LINC01093, long intergenic non-protein coding RNA 1093; T, tumor samples; NT, non-tumor tissue samples; HR, hazard ratio; RPKM, reads per kilobase per million mapped reads; TPM, transcripts per million.](etm-18-05-3853-g00){#f1-etm-0-0-8046}

![LINC01093 is a potential target of miR-96-5p. (A) Regulatory network of LINC01093, miRNAs and mRNAs: Blue nodes, LINC01093; green nodes, miRNA; pink nodes, mRNA. (B) Flow chart for the *in silico* prediction of LINC01093-miRNA-mRNA pairs. (C) Validation of miRNA expression using data from The Cancer Genome Atlas. Kaplan-Meier analysis of overall survival for patients with hepatocellular carcinoma with high vs. low expression of (D) miR-96-5p, (E) miR-627-3p and (F) miR-30b-3p. miRNA, microRNA; hsa, *Homo sapiens*; LINC01093, long intergenic non-protein coding RNA 1093; T, tumor samples; NT, non-tumor tissue samples; HR, hazard ratio. NTN4, nerve guidance factor 4; APOC3, apolipoprotein C3; CCL16, C-C motif chemokine ligand 16; CYP1A2, cytochrome P450 1A2; FAM83F, family with sequence similarity 83; MSMO1, methylsterol monooxygenase 1; SIGLEC1, sialic acid binding Ig like lectin 1; SLC19A3, solute carrier family 19 member 3; SULT1E1, sulfotransferase family 1E member 1; TBXA2R, thromboxane A2 receptor; TMEM154, transmembrane protein 154; ZFAND5, zinc finger AN1-type containing 5; SMAD5, SMAD family member 5; POLR2D, RNA polymerase II subunit D; ZNF385, zinc finger protein 385A, HIF3A, hypoxia inducible factor 3 subunit α; ZNF286B, zinc finger protein 286B; B3GALT5, β-1,3-galactosyltransferase 5; BLOC1S3, biogenesis of lysosomal organelles complex 1 subunit 3; DST, dystonin; LPP, LIM domain containing preferred translocation partner in lipoma.](etm-18-05-3853-g01){#f2-etm-0-0-8046}

![ZFAND5 is a candidate target of miR-96-5p. (A) Expression of selected miR-96-5p target genes. (B) The aberrant expression of the target genes was validated using The Cancer Genome Atlas dataset. Kaplan-Meier analysis of overall survival for patients with hepatocellular carcinoma with high vs. low expression of (C) ZFAND5 and (D) NTN4. ZFAND5, zinc finger AN1-type containing 5; miRNA, microRNA; T, tumor samples; NT, non-tumor tissue samples; HR, hazard ratio; NTN4, netrin 4; LPP, LIM domain containing preferred translocation partner in lipoma.](etm-18-05-3853-g02){#f3-etm-0-0-8046}

![Functional analyses of the ZFAND5 interactome. (A) ZFAND5 interactors identified by different experimental systems. (B) Gene Ontology analysis of ZFAND5 interactors in the category Biological Process. (C) Reactome pathway analysis of ZFAND5 interactors. Visualization of genes involved in (D) Biological Process terms and (E) reactome pathways. The grey nodes indicate genes and other colored nodes represent different GO terms or pathways. The node size and color represent enrichment significance; the larger the node, the higher enrichment significance of the pathway. ZFAND5, zinc finger AN1-type containing 5. SQSTM1, sequestosome 1; PSMD6, proteasome 26S subunit non-ATPase 6; IKBKG, inhibitor of nuclear factor κB kinase regulatory subunit γ; TRAF6, TNF receptor associated factor 6; UBC, ubiquitin C; APP, amyloid β precursor protein; TOMM34, translocase of outer mitochondrial membrane 34; SRP19, signal recognition particle 19; MAP3K1, mitogen-activated protein kinase kinase kinase 1; CETN1, centrin 1; SMURF1, SMAD specific E3 ubiquitin protein ligase 1; UBLCP1, ubiquitin like domain containing CTD phosphatase 1; ATP6V1H, ATPase H^+^ transporting V1 subunit H; WIPF2, WAS/WASL interacting protein family member 2.](etm-18-05-3853-g03){#f4-etm-0-0-8046}

[^1]: Contributed equally
